About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Invests $20 million in Editas Medicine

NEW YORK, NEW YORK – August 10, 2015 – Deerfield Management Company, L.P.’s venture capital fund, Deerfield Healthcare Innovations Fund, L.P, today announced its first therapeutics-based investment by participating, along with Deerfield Private Design Fund III, in providing financing to Editas Medicine.  In total, Deerfield invested $20 million in this early-stage institutional financing.

Editas Medicine is at the forefront ofdeveloping CRISPR/Cas9, a genome-editing technology, which makes it possible to turn off or edit disease-causing genes, potentially leading to a cure. Deerfield’s capital will support the advancement of multiple new therapies into studies which can prove their utility. 

“Gene editing has the potential to cure diseases that currently result in significant disability or death,” said Jim Flynn, managing partner of Deerfield. “Given the dozens of important disease targets where gene editing can play an important role and the transformative effect on lives that these new therapies can offer, Editas Medicine is the ideal initial therapeutic company investment by the Healthcare Innovations Fund.”

“Deerfield’s commitment to changing medical practice through innovative science and thoughtful investing matches our own, and we are privileged to have them as part of our team to help build Editas,” said Katrine Bosley, CEO of Editas Medicine. “Deerfield has a long track record of supporting emerging biotechnology companies and helping them navigate the challenges of bringing important new medicines to patients.”

The Deerfield Healthcare Innovations Fund, which launched in July, focuses on investing in early-stage companies with transformative new healthcare products and services.  All of the fund’s incentive profits go to the Deerfield Partnership Foundation to provide healthcare services for underserved children and promote medical innovation.

About Editas

Editas Medicine is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The Company was founded by pioneers and worldleaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The Company’s mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically driven diseases.

For more information, visit

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

Formore information, please visit


Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]